© Niclas Jessen Studio/Bracco Imaging SpARadiopharmaceuticals specialist Blue Earth Therapeutics Ltd will use a U$76.5m Series A financing to finance Phase II development of its targeted prostate cancer radiopharmaceuticals Lutetium (177-Lu) rhPSMA-10.1 and Actinium (225-Ac) rhPSMA-10.1.
EniferAs the first Nordic company seeking Novel Food approval for a mycoprotein ingredient, Finnish Enifer has filed a authorisation application for it brand PEKILO to the EU food watchdog EFSA.
Knowledge Seeker - wikipedia.orgDigital pathology specialist AIgnostics GmbH has topped up its cash position to US$55m with a US$34m Series B financing. The money will be used to optimise the company’s RudolfV Foundation Model and to develop and offer new services for target and biomarker identification selection, particularly in the US pharma market.
Resalis/VimeoItalian obesity gene therapy developer Resalis Therapeutics srl has gained an equity investment from French pharma major Sanofi SA sufficient to finance its miRNA-22 antisense blocker RES-010 through Phase II proof-of-concept.
UCB SABelgian UCB SA and British Cancer UK have started a second clinical study within their multi-year partnership to evaluate the safety and tolerable dose of UCB4594 in patients with advanced cancers.
123rf.com/IculigAnother strong financing round for Belgian Agomab NV. Sanofi is joining the band wagon of targeting the TGFbeta receptor.
Rentschler Biopharma SERentschler Biopharma announces largest single investment in the higher double-digit range at its headquarters in Germany for construction of a new buffer media facility in Laupheim.
Roche, Herzog&De MeuronRoche drops a third Alzheimer’s candidate this year, leaving a partnership with UCB just four years after agreeing to work together on new treatments for the neurological disease.
Biotech firm Nuclera raises $75M to expand its cutting-edge protein discovery system, speeding up breakthroughs in labs worldwide.
Image by freepikPurespring Therapeutics, a pioneering gene therapy company focused on transforming kidney disease treatment, has raised £80 (€96m) in an oversubscribed Series B round. Led by Sofinnova Partners, this funding also drew support from Gilde Healthcare, Forbion, British Patient Capital, and Syncona Limited.